Basis: FMP quote price / unrounded FMP forward EPS in the trading currency, available after its recorded retrieval time. Source: stored company filings and market data; unavailable inputs remain N/A.
The forward PE ratio is N/A as of 2026-10-06T15:45:23.334Z.
Consensus retrieved: 2026-10-06T08:34:35.090Z. This records retrieval, including cache reads, rather than vendor publication. The calculation uses the separately dated price and estimate available at its as-of time.
Calculation as of: 2026-10-06T15:45:23.334Z.
Quote observation: 2026-10-06T15:45:10.000Z. Amounts in USD. The price header may show a later quote.
FMP input reference: 6c72f4ef7e8e092e42bf2675274103acb858a2e333bfebc02596e546aa7f2fe4
Forward PE Ratio (N/A) = Dated Quote Price ($5.86) / Consensus Forward EPS ($-0.20)
FORWARD PE RATIO
N/A
AdaptHealth Corp.
Market Cap
$796.60M
Forward PE Ratio
N/A
| NAME | MARKET CAP | FORWARD PE RATIO |
|---|---|---|
| AdaptHealth Corp. (AHCO) | $796.60M | N/A |
| Gyre Therapeutics, Inc. (GYRE)vs › | $799.93M | N/A |
| Geron Corporation (GERN)vs › | $789.07M | N/A |
| Apnimed, Inc. (APMD)vs › | $804.43M | N/A |
| Lexicon Pharmaceuticals, Inc. (LXRX)vs › | $785.87M | N/A |
| InMode Ltd. (INMD)vs › | $805.59M | 10.81 |
| Attovia Therapeutics, Inc. (ATTO)vs › | $774.54M | N/A |
| Mesa Laboratories, Inc. (MLAB)vs › | $773.58M | N/A |
| Ardelyx, Inc. (ARDX)vs › | $817.67M | N/A |
| Design Therapeutics, Inc. (DSGN)vs › | $769.08M | N/A |
Trailing P/E
N/A
reported TTM EPS
Forward P/E
N/A
consensus EPS · fiscal year ending 2026-12-31
At the dated quote price of $5.86, each upcoming fiscal year's consensus EPS implies a different multiple — how quickly the price is "paid down" by expected earnings if the estimates hold.
| Fiscal year end | Consensus EPS | Estimate range | Analysts | Implied P/E |
|---|---|---|---|---|
| 2026-12-31 | $-0.20 | $-0.21 – $-0.20 | 3 | n/m |
| 2027-12-31 | $-0.02 | $-0.03 – $-0.02 | 3 | n/m |
| 2028-12-31 | $0.31 | $-0.24 – $1.17 | 3 | 18.9x |
Source: FMP analyst consensus estimates, refreshed with the daily precompute. "n/m" = the consensus EPS is not positive, so a multiple is undefined. There is no forward P/E history chart here because charting one would require the estimates as they stood in the past, which we do not store — see the trailing P/E history for how the realized multiple has moved.
PE Ratio = Share Price / Diluted EPS (TTM)
The price-to-earnings ratio measures how much investors pay for each dollar of trailing earnings. A lower PE can indicate a cheaper valuation; a higher PE implies higher growth expectations.
Expanded definitions: Investopedia, Wikipedia, Corporate Finance Institute
